top of page
News, Events and Updates
Search
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
May 9, 2024
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
May 2, 2024
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Apr 11, 2024
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar 25, 2024
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Mar 18, 2024
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
Feb 26, 2024
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
Feb 7, 2024
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Feb 1, 2024
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humans
Jan 24, 2024
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Jan 16, 2024
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
Jan 8, 2024
3
4
5
6
7
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
